Researchers analyzed 51 longitudinal studies to assess how 110 DNA methylation biomarkers respond to different classes of longevity interventions. Pharmacological treatments showed the strongest and most consistent effects on epigenetic aging markers, while lifestyle and supplement interventions produced weaker responses, suggesting that validated biomarkers could accelerate evaluation of anti-aging therapies from decades to years or months.
Key Points
- Pharmacological interventions produced significantly larger biomarker effects than lifestyle, supple
- TNF-reducing therapies showed replicated effects across multiple studies and biomarkers, meeting con
- Epigenetic clocks currently lack sufficient validation for use as surrogate endpoints in human longe
Longevity Analysis
The responsiveness hierarchy revealed here has immediate practical implications: it establishes which intervention types produce measurable changes in biological aging signals, and it exposes the gap between biomarker popularity and clinical utility. For practitioners evaluating longevity strategies, this work clarifies that pharmacological approaches—particularly those targeting inflammation and metabolic pathways—generate detectable shifts in epigenetic markers within realistic timeframes, whereas lifestyle and supplement interventions require longer observation periods to register meaningful changes. The emphasis on replication addresses a critical need: without consistency across studies, a biomarker cannot reliably guide clinical decisions. This framework helps distinguish between biomarkers that merely correlate with age and those that genuinely track intervention efficacy, which is essential for designing trials that measure real health improvement rather than statistical artifa
Original published by LifeSpan.io, by Anna Drangowska-Way.